Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Accumulated Expenses: 2021-2022

Historic Accumulated Expenses for ProQR Therapeutics N.V (PRQR) over the last 2 years, with Dec 2022 value amounting to $8.9 million.

  • ProQR Therapeutics N.V's Accumulated Expenses fell 28.00% to $8.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $8.9 million, marking a year-over-year decrease of 28.00%. This contributed to the annual value of $8.9 million for FY2022, which is 30.40% down from last year.
  • ProQR Therapeutics N.V's Accumulated Expenses amounted to $8.9 million in FY2022, which was down 30.40% from $12.7 million recorded in FY2021.
  • ProQR Therapeutics N.V's Accumulated Expenses' 5-year high stood at $12.7 million during FY2021, with a 5-year trough of $8.9 million in FY2022.
  • In the last 2 years, ProQR Therapeutics N.V's Accumulated Expenses had a median value of $10.8 million in 2022 and averaged $10.8 million.
  • Data for ProQR Therapeutics N.V's Accumulated Expenses shows a maximum YoY plummeted of 30.40% (in 2022) over the last 5 years.
  • ProQR Therapeutics N.V's Accumulated Expenses (Yearly) stood at $12.7 million in 2021, then crashed by 30.40% to $8.9 million in 2022.